V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10004807 | 10003016 | 1.95 | 84 | Palliative (P) | 2015-06-17 | 2015-06-17 | Cetuximab + Radiotherapy Load | N | N | 10546601 | BEP |
| 10004808 | 10003016 | 1.56 | null | Palliative (P) | 2017-01-21 | 2017-01-21 | Bevacizumab 7.5mg/kg | 02 | N | 10546601 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10004809 | 10003017 | null | 83 | Palliative (P) | 2017-05-12 | 2017-05-16 | MYELOMA XI TRIAL | 02 | null | 10546671 | ECF |
| 10004810 | 10003017 | 1.61 | 70 | Curative (C) | 2014-10-11 | 2014-10-22 | TCH (21 day Trastuzumab) Maint | N | null | 10546671 | DABRAFENIB + TRAMETINIB |
| 10004811 | 10003018 | 1.6 | 71.3 | Palliative (P) | 2015-06-24 | 2015-07-02 | Capecitabine + Mitomycin | N | N | 10546744 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004812 | 10003018 | 1.73 | 73.6 | Disease modification (D) | 2016-04-12 | 2016-04-12 | RIALTO TRIAL | N | N | 10546744 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10004813 | 10003019 | 1.72 | 90.6 | Adjuvant (A) | 2014-05-01 | 2014-05-07 | RIALTO TRIAL | 02 | N | 10546808 | CETUXIMAB + IRINOTECAN + MDG |
| 10004814 | 10003020 | 1.67 | 59 | Disease modification (D) | 2016-07-13 | 2016-07-14 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 2 | N | 10546969 | CHOP R + METHOTREXATE |
| 10004815 | 10006726 | 1.76 | 83.6 | Curative (C) | null | 2016-08-16 | Alemtuz+Fludara+Melphalan RIC MUD | null | null | 10547014 | CETUXIMAB + IRINOTECAN + MDG |
| 10004816 | 10003021 | 1.7 | 92 | Neo-adjuvant (N) | 2017-01-18 | 2017-01-19 | CISPLATIN + FLUOROURACIL | 02 | N | 10547060 | CISPLATIN + FLUOROURACIL |
| 10004817 | 10003022 | 1.6 | 0 | Curative (C) | 2017-01-28 | 2017-01-29 | Cisplatin + Doxorubicin | 2 | N | 10547111 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10004818 | 10006727 | null | 79 | Palliative (P) | 2015-10-20 | 2015-10-20 | METHOTREXATE HIGH DOSE + RITUXIMAB | N | N | 10547153 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10004819 | 10003023 | 1.77 | 73.8 | Palliative (P) | 2017-09-14 | 2017-09-29 | Vemurafenib | 99 | null | 10547331 | HCX |
| 10004820 | 10003023 | 1.73 | 85.9 | Palliative (P) | 2015-02-08 | 2015-02-14 | Capecitabine + Cisplatin + RT | N | N | 10547331 | MYELOMA XI TRIAL |
| 10004821 | 10003023 | 1.7 | 63.3 | Palliative (P) | 2016-07-27 | 2016-07-27 | CAPECITABINE + MITOMYCIN + RT | N | N | 10547331 | CETUXIMAB + IRINOTECAN |
| 10004822 | 10003024 | 1.61 | 85.4 | Curative (C) | 2018-08-01 | 2018-08-02 | Pazopanib | N | N | 10547463 | TEMOZOLOMIDE |
| 10004823 | 10003025 | 1.56 | 63.9 | Palliative (P) | 2015-12-17 | 2015-12-26 | EC + DOCETAXEL | N | N | 10547505 | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10004824 | 10003025 | null | 60.7 | Adjuvant (A) | 2018-02-05 | 2018-02-07 | Capecitabine (14 day) + Irinotecan | 1 | null | 10547505 | GEMCITABINE + NAB-PACLITAXEL |
| 10004825 | 10003025 | null | 60 | Curative (C) | 2018-06-09 | 2018-06-13 | CAPECITABINE + MITOMYCIN + RT | N | N | 10547505 | OCTREOTIDE |
| 10004826 | 10003026 | 1.6 | 0 | Disease modification (D) | 2018-09-04 | 2018-09-04 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 2 | N | 10547701 | CETUXIMAB + IRINOTECAN + MDG |
| 10004827 | 10003027 | 1.56 | 76 | Disease modification (D) | 2016-02-19 | 2016-02-19 | Cisplatin +Fluorouracil (2 wk) | N | N | 10547710 | CHLVPP |
| 10004828 | 10006730 | 1.52 | 51.8 | Disease modification (D) | 2018-03-20 | 2018-03-22 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10547746 | DABRAFENIB + TRAMETINIB |
| 10004829 | 10006730 | 0 | 84.5 | Curative (C) | 2016-09-14 | 2016-09-30 | Sorafenib | N | N | 10547746 | IPILIMUMAB |
| 10004830 | 10006730 | 1.66 | 67.2 | Palliative (P) | 2017-05-14 | 2017-05-15 | Cyclophosphamide + Docetaxel | N | N | 10547746 | AC |
| 10004831 | 10003028 | 1.69 | 55.3 | Palliative (P) | 2015-11-01 | 2015-11-04 | CISPLATIN + FLUOROURACIL + RT | 2 | N | 10547854 | PANITUMUMAB |
| 10004832 | 10003028 | 1.66 | 116 | Palliative (P) | 2017-03-27 | 2017-03-27 | AML 18 TRIAL | N | null | 10547854 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10004833 | 10003028 | 1.68 | 0 | Palliative (P) | 2017-11-12 | 2017-11-15 | DA 3 + 10 | N | N | 10547854 | CETUXIMAB + IRINOTECAN + MDG |
| 10004834 | 10008857 | 1.69 | 75.3 | Curative (C) | 2015-05-02 | 2015-05-14 | Cisplatin +Fluorouracil (3 wk) | N | N | 10547894 | CHLORAMBUCIL + RITUXIMAB |
| 10004835 | 10003029 | 1.74 | 73 | Palliative (P) | 2014-07-29 | 2014-08-05 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 10547918 | IPILIMUMAB + NIVOLUMAB |
| 10004836 | 10006732 | 1.79 | null | Disease modification (D) | 2018-02-20 | 2018-03-01 | Ofatumumab Monthly | 2 | N | 10547946 | DA |
| 10004837 | 10003030 | 1.89 | null | Palliative (P) | 2016-08-31 | 2016-09-01 | Capecitabine (21days) + Carboplatin | 02 | N | 10548076 | FLAG + IDARUBICIN |
| 10004838 | 10003031 | 1.87 | 76.9 | Adjuvant (A) | 2015-04-14 | 2015-05-06 | CODOX M | N | N | 10548111 | EP |
| 10004839 | 10003031 | 1.71 | 81.5 | Disease modification (D) | 2016-11-28 | 2016-12-10 | TEMOZOLOMIDE | N | N | 10548111 | IRINOTECAN + MDG + PANITUMUMAB |
| 10004840 | 10003032 | 1.54 | 65 | Curative (C) | 2016-08-22 | 2016-09-20 | CETUXIMAB + IRINOTECAN + MDG | 2 | N | 10548224 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10004841 | 10003033 | 1.66 | 58.3 | Curative (C) | 2016-05-04 | 2016-05-04 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | N | 10548238 | CAPECITABINE + CARBOPLATIN |
| 10004842 | 10003034 | 0 | 43.7 | Curative (C) | null | 2015-10-09 | MPV (cycle 1-4) | N | N | 10548344 | RUXOLITINIB |
| 10004843 | 10003034 | 1.75 | 63.4 | Palliative (P) | 2018-11-15 | 2018-11-21 | MPV (cycle 1-4) | 02 | N | 10548344 | PAZOPANIB |
| 10004844 | 10003034 | 0 | 78.7 | Curative (C) | 2018-01-30 | 2018-02-13 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 1 | N | 10548344 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10004845 | 10003035 | null | 70.8 | Disease modification (D) | null | 2016-08-29 | ARISTOTLE TRIAL | N | N | 10548501 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 10004846 | 10003036 | 1.71 | 61.1 | Curative (C) | 2016-12-22 | 2017-01-04 | Capecitabine + Cisplatin + RT | N | N | 10548566 | NOT MATCHED |
| 10004847 | 10003037 | 155 | 91.2 | Adjuvant (A) | 2018-09-27 | 2018-10-04 | IBRUTINIB | Y | N | 10548637 | ERLOTINIB |
| 10004848 | 10006735 | null | 81.4 | Palliative (P) | 2017-03-20 | 2017-03-20 | Cyclophos + Dex + Lenalidomide | 02 | null | 10548681 | HCX |
| 10004849 | 10003038 | 1.75 | 81.8 | Disease modification (D) | 2017-03-14 | 2017-03-31 | Cladribine (subcut) 5 days | N | N | 10548703 | CLADRIBINE |
| 10004850 | 10003039 | 1.63 | 56.8 | Palliative (P) | 2018-09-24 | 2018-09-26 | TRASTUZUMAB | 2 | N | 10548704 | CHLVPP |
| 10004851 | 10003039 | 1.62 | null | Not known (9) | 2018-01-18 | 2018-01-20 | DA 3 + 10 | N | N | 10548704 | CARFILZOMIB + CYCLOPHOSPHAMIDE |
| 10004852 | 10008229 | 1.73 | 86 | Disease modification (D) | 2015-04-20 | 2015-04-26 | Mitomycin Intravesical | null | N | 10548786 | SORAFENIB |
| 10004853 | 10003040 | 1.75 | 67.8 | null | 2017-07-31 | 2017-10-23 | Vemurafenib | N | N | 10548822 | ECF |
| 10004854 | 10003040 | 1.72 | null | Palliative (P) | null | 2016-12-23 | Cytarabine Low Dose | N | N | 10548822 | GEFITINIB |
| 10004855 | 10003040 | 1.65 | 62 | Disease modification (D) | 2016-10-27 | 2016-10-31 | CISPLATIN + VINORELBINE + RT | 2 | Y | 10548822 | ERLOTINIB |
| 10004856 | 10009127 | 1.69 | 81.9 | Palliative (P) | 2016-06-28 | 2016-06-28 | BLEOMYCIN | N | N | 10548878 | CYTARABINE |